Leptin signaling mediates obesity-associated CSC enrichment and EMT in preclinical TNBC models

Molecular Cancer Research

Volumn 16, Issue 5, 2018, Pages 869-879

  Bowers, Laura W ^a,b   Rossi, Emily L ^a,b   McDonell, Shannon B ^a   Doerstling, Steven S ^a   Khatib, Subreen A ^a   Lineberger, Claire G ^a   Albright, Jody E ^b   Tang, Xiaohu ^c   DeGraffenried, Linda A ^d   Hursting, Stephen D ^a,b  

^a University of North Carolina at Chapel Hill   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c MICHIGAN TECHNOLOGICAL UNIVERSITY   (United States)

^d University of Texas at Austin   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ALDEHYDE DEHYDROGENASE; GASTRIC INHIBITORY POLYPEPTIDE; GHRELIN; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; INSULIN; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEPTIN; LEPTIN RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; NOTCH1 RECEPTOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN KINASE B; RESISTIN; SOMATOMEDIN C; TRANSCRIPTION FACTOR FOXC2; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SOX2; TRANSCRIPTION FACTOR ZEB1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; TWIST RELATED PROTEIN 2; VIMENTIN; WNT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY FAT; CANCER STEM CELL; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DIET INDUCED OBESITY; ENZYME ACTIVITY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION; IN VITRO STUDY; MDA-MB-231 CELL LINE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA SEQUENCE; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; UPREGULATION; ANIMAL; GENETICS; HUMAN; METABOLISM; OBESITY; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; LEPTIN; MICE; NEOPLASTIC STEM CELLS; OBESITY; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 85047757067     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-17-0508     Document Type: Article

References (47)

1. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012;307:491–7.
2. Protani M, Coory M, Martin JH. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat 2010;123:627–35.
3. Bao PP, Cai H, Peng P, Gu K, Su Y, Shu XO, et al. Body mass index and weight change in relation to triple-negative breast cancer survival. Cancer Causes Control 2016;27:229–36.
4. Widschwendter P, Friedl TW, Schwentner L, DeGregorio N, Jaeger B, Schramm A, et al. The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial. Breast Cancer Res 2015;17:129.
5. Litton JK, Gonzalez-Angulo AM, Warneke CL, Buzdar AU, Kau SW, Bondy M, et al. Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer. J Clin Oncol 2008;26:4072–7.
6. Chen S, Chen CM, Zhou Y, Zhou RJ, Yu KD, Shao ZM. Obesity or overweight is associated with worse pathological response to neoadjuvant chemotherapy among Chinese women with breast cancer. PLoS One 2012;7:e41380.
7. Iwase T, Sangai T, Nagashima T, Sakakibara M, Sakakibara J, Hayama S, et al. Impact of body fat distribution on neoadjuvant chemotherapy outcomes in advanced breast cancer patients. Cancer Med 2016;5:41–8.
8. Pajares B, Pollan M, Martin M, Mackey JR, Lluch A, Gavila J, et al. Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis. Breast Cancer Res 2013;15:R105.
9. Del Fabbro E, Parsons H, Warneke CL, Pulivarthi K, Litton JK, Dev R, et al. The relationship between body composition and response to neoadjuvant chemotherapy in women with operable breast cancer. Oncologist 2012; 17:1240–5.
10. Wei W, Lewis MT. Identifying and targeting tumor-initiating cells in the treatment of breast cancer. Endocr Relat Cancer 2015;22:R135–55.
11. Dunlap SM, Chiao LJ, Nogueira L, Usary J, Perou CM, Varticovski L, et al. Dietary energy balance modulates epithelial-to-mesenchymal transition and tumor progression in murine claudin-low and basal-like mammary tumor models. Cancer Prev Res 2012;5:930–42.
12. Zheng Q, Dunlap SM, Zhu J, Downs-Kelly E, Rich J, Hursting SD, et al. Leptin deficiency suppresses MMTV-Wnt-1 mammary tumor growth in obese mice and abrogates tumor initiating cell survival. Endocr Relat Cancer 2011;18:491–503.
13. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Taylor SK, et al. Insulin- and obesity-related variables in early-stage breast cancer: correlations and time course of prognostic associations. J Clin Oncol 2012;30: 164–71.
14. Ishikawa M, Kitayama J, Nagawa H. Enhanced expression of leptin and leptin receptor (OB-R) in human breast cancer. Clin Cancer Res 2004; 10:4325–31.
15. Garofalo C, Koda M, Cascio S, Sulkowska M, Kanczuga-Koda L, Golaszewska J, et al. Increased expression of leptin and the leptin receptor as a marker of breast cancer progression: possible role of obesity-related stimuli. Clin Cancer Res 2006;12:1447–53.
16. Miyoshi Y, Funahashi T, Tanaka S, Taguchi T, Tamaki Y, Shimomura I, et al. High expression of leptin receptor mRNA in breast cancer tissue predicts poor prognosis for patients with high, but not low, serum leptin levels. Int J Cancer 2006;118:1414–9.
17. Xu J, Prosperi JR, Choudhury N, Olopade OI, Goss KH. beta-Catenin is required for the tumorigenic behavior of triple-negative breast cancer cells. PLoS One 2015;10:e0117097.
18. O'Flanagan CH, Rossi EL, McDonell SB, Chen X, Tsai YH, Parker JS, et al. Metabolic reprogramming underlies metastatic potential in an obesity-responsive murine model of metastatic triple negative breast cancer. NPJ Breast Cancer 2017;3:26.
19. Rossi EL, Dunlap SM, Bowers LW, Khatib SA, Doerstling SS, Smith LA, et al. Energy balance modulation impacts epigenetic reprogramming, ERalpha and ERbeta expression, and mammary tumor development in MMTV-neu transgenic mice. Cancer Res 2017;77:2500–11.
20. Korkaya H, Paulson A, Iovino F, Wicha MS. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 2008;27:6120–30.
21. Chang CC, Wu MJ, Yang JY, Camarillo IG, Chang CJ. Leptin-STAT3-G9a signaling promotes obesity-mediated breast cancer progression. Cancer Res 2015;75:2375–86.
22. Feldman DE, Chen C, Punj V, Tsukamoto H, Machida K. Pluripotency factor-mediated expression of the leptin receptor (OB-R) links obesity to oncogenesis through tumor-initiating stem cells. Proc Natl Acad Sci U S A 2012;109:829–34.
23. Kato S, Abarzua-Catalan L, Trigo C, Delpiano A, Sanhueza C, Garcia K, et al. Leptin stimulates migration and invasion and maintains cancer stem-like properties in ovarian cancer cells: an explanation for poor outcomes in obese women. Oncotarget 2015;6:21100–19.
24. Bowers LW, Cavazos DA, Maximo IX, Brenner AJ, Hursting SD, deGraffenried LA. Obesity enhances nongenomic estrogen receptor crosstalk with the PI3K/Akt and MAPK pathways to promote in vitro measures of breast cancer progression. Breast Cancer Res 2013; 15:R59.
25. Zheng Q, Banaszak L, Fracci S, Basali D, Dunlap SM, Hursting SD, et al. Leptin receptor maintains cancer stem-like properties in triple negative breast cancer cells. Endocr Relat Cancer 2013;20:797–808.
26. Wang L, Tang C, Cao H, Li K, Pang X, Zhong L, et al. Activation of IL-8 via PI3K/Akt-dependent pathway is involved in leptin-mediated epithelial-mesenchymal transition in human breast cancer cells. Cancer Biol Ther 2015;16:1220–30.
27. Yan D, Avtanski D, Saxena NK, Sharma D. Leptin-induced epithelial-mesenchymal transition in breast cancer cells requires beta-catenin activation via Akt/GSK3- and MTA1/Wnt1 protein-dependent pathways. J Biol Chem 2012;287:8598–612.
28. Wei L, Li K, Pang X, Guo B, Su M, Huang Y, et al. Leptin promotes epithelial-mesenchymal transition of breast cancer via the upregulation of pyruvate kinase M2. J Exp Clin Cancer Res 2016;35:166.
29. Thiagarajan PS, Zheng Q, Bhagrath M, Mulkearns-Hubert EE, Myers MG, Lathia JD, et al. STAT3 activation by leptin receptor is essential for TNBC stem cell maintenance. Endocr Relat Cancer 2017;24:415–26.
30. Mishra AK, Parish CR, Wong ML, Licinio J, Blackburn AC. Leptin signals via TGFB1 to promote metastatic potential and stemness in breast cancer. PLoS One 2017;12:e0178454.
31. Giordano C, Chemi F, Panza S, Barone I, Bonofiglio D, Lanzino M, et al. Leptin as a mediator of tumor-stromal interactions promotes breast cancer stem cell activity. Oncotarget 2016;7:1262–75.
32. Strong AL, Ohlstein JF, Biagas BA, Rhodes LV, Pei DT, Tucker HA, et al. Leptin produced by obese adipose stromal/stem cells enhances proliferation and metastasis of estrogen receptor positive breast cancers. Breast Cancer Res 2015;17:112.
33. Harbuzariu A, Rampoldi A, Daley-Brown DS, Candelaria P, Harmon TL, Lipsey CC, et al. Leptin-Notch signaling axis is involved in pancreatic cancer progression. Oncotarget 2017;8:7740–52.
34. Esper RM, Dame M, McClintock S, Holt PR, Dannenberg AJ, Wicha MS, et al. Leptin and adiponectin modulate the self-renewal of normal human breast epithelial stem cells. Cancer Prev Res 2015;8:1174–83.
35. Liu S, Patel SH, Ginestier C, Ibarra I, Martin-Trevino R, Bai S, et al. MicroRNA93 regulates proliferation and differentiation of normal and malignant breast stem cells. PLoS Genet 2012;8:e1002751.
36. Chin YR, Yoshida T, Marusyk A, Beck AH, Polyak K, Toker A. Targeting Akt3 signaling in triple-negative breast cancer. Cancer Res 2014;74:964–73.
37. O'Hurley G, Daly E, O'Grady A, Cummins R, Quinn C, Flanagan L, et al. Investigation of molecular alterations of AKT-3 in triple-negative breast cancer. Histopathology 2014;64:660–70.
38. Nakatani K, Thompson DA, Barthel A, Sakaue H, Liu W, Weigel RJ, et al. Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J Biol Chem 1999;274:21528–32.
39. Mani SA, Yang J, Brooks M, Schwaninger G, Zhou A, Miura N, et al. Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associatedwithaggressivebasal-likebreastcancers.ProcNatlAcadSciUSA 2007;104:10069–74.
40. Paranjape AN, Soundararajan R, Werden SJ, Joseph R, Taube JH, Liu H, et al. Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell properties. Oncogene 2016;35: 5963–76.
41. Hollier BG, Tinnirello AA, Werden SJ, Evans KW, Taube JH, Sarkar TR, et al. FOXC2 expression links epithelial-mesenchymal transition and stem cell properties in breast cancer. Cancer Res 2013;73:1981–92.
42. Fang X, Cai Y, Liu J, Wang Z, Wu Q, Zhang Z, et al. Twist2 contributes to breast cancer progression by promoting an epithelial-mesenchymal transition and cancer stem-like cell self-renewal. Oncogene 2011;30:4707–20.
43. Liu AY, Cai Y, Mao Y, Lin Y, Zheng H, Wu TTwist2 promotes self-renewal of liver cancer stem-like cells by regulating CD24. Carcinogenesis 2014; 35:537–45.
44. Wang T, Li Y, Wang W, Tuerhanjiang A, Wu Z, Yang R, et al. Twist2, the key Twist isoform related to prognosis, promotes invasion of cervical cancer by inducing epithelial-mesenchymal transition and blocking senescence. Hum Pathol 2014;45:1839–46.
45. Cai J, Tian AX, Wang QS, Kong PZ, Du X, Li XQ, et al. FOXF2 suppresses the FOXC2-mediated epithelial-mesenchymal transition and multidrug resistance of basal-like breast cancer. Cancer Lett 2015;367:129–37.
46. Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol 2016;13:674–90.
47. Abramson VG, Mayer IA. Molecular heterogeneity of triple negative breast cancer. Curr Breast Cancer Rep 2014;6:154–8.